Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue:    
Tc99m tilmanocept royalty revenue $ 16,000  
Grant and other revenue 275,650 $ 580,030
Revenue 276,445 580,030
Cost of goods sold 318
Gross profit 276,127 580,030
Operating expenses:    
Research and development expenses 998,956 705,274
Selling, general and administrative 1,776,372 3,022,434
Total operating expenses 2,775,328 3,727,708
Loss from operations [1] (2,499,201) (3,147,678)
Other income (expense):    
Interest income, net 31,387 24,112
Change in fair value of financial instruments 140,485
Loss on extinguishment of debt (4,265,434) (1,314,102)
Other, net (4,714) (21,604)
Total other expense, net (4,238,761) [2] (1,171,109)
Loss before income taxes (6,737,962) (4,318,787)
Benefit from income taxes 0 1,454,172
Loss from continuing operations (6,737,962) (2,864,615)
Discontinued operations, net of tax effect:    
Loss from discontinued operations (255,861)
Gain on sale 88,701,501
Net (loss) income (6,737,962) 85,581,025
Less loss attributable to noncontrolling interest (9) (202)
Net (loss) income attributable to common stockholders $ (6,737,953) $ 85,581,227
(Loss) income per common share (basic):    
Continuing operations (in dollars per share) $ (0.04) $ (0.02)
Discontinued operations (in dollars per share) 0.55
Attributable to common stockholders (in dollars per share) $ (0.04) $ 0.53
Weighted average shares outstanding (basic) (in shares) 162,269,012 160,376,476
(Loss) income per common share (diluted):    
Continuing operations (in dollars per share) $ (0.04) $ (0.02)
Discontinued operations (in dollars per share) 0.54
Attributable to common stockholders (in dollars per share) $ (0.04) $ 0.52
Weighted average shares outstanding (diluted) (in shares) 162,269,012 164,871,955
Royalty [Member]    
Revenue:    
Tc99m tilmanocept royalty revenue $ 795
[1] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.